Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 7:51 AM ET

Healthcare Equipment and Supplies

Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...

7000 Shoreline Court

Suite 250

South San Francisco, CA 94080

United States

Founded in 2006

167 Employees

Phone:

650-243-6300

Fax:

650-243-6301

Key Executives for Veracyte, Inc.

Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Age: 57
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Age: 55
Total Annual Compensation: $300.0K
Chief Operating Officer
Age: 46
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

Veracyte, Inc. Key Developments

Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer

Veracyte, Inc. announced the appointment of Neil M. Barth, M.D., F.A.C.P., as chief medical officer, effective immediately. Dr. Barth has more than 30 years of experience providing and directing patient care for healthcare-provider organizations and diagnostics companies. Most recently, he served as chief medical officer for Agendia NV. Prior to that, Dr. Barth served as chief medical officer for Ambry Genetics.

Veracyte, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015 ; Reiterates Guidance for the Year 2015

Veracyte, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $11,908,000, loss from operations of $9,074,000, net loss and comprehensive loss of $9,136,000 or $0.35 per basic and diluted share compared to the revenue of $8,677,000, loss from operations of $6,561,000, net loss and comprehensive loss of $6,655,000 or $0.31 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported revenue of $23,126,000, loss from operations of $16,627,000, net loss and comprehensive loss of $16,746,000 or $0.69 per basic and diluted share compared to the revenue of $16,153,000, loss from operations of $13,136,000, net loss and comprehensive loss of $13,329,000 or $0.63 per basic and diluted share for the same period a year ago. The company reiterated its 2015 annual revenue guidance of $48 million to $53 million, as well as its forecast to achieve annual Afirma GEC test volume in the range of 19,000 to 21,000.

Veracyte, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Veracyte, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 13, 2015

Similar Private Companies By Industry

Company Name Region
InfraredMed Corporation United States
Custom Mobility, Inc. United States
Pro Med Instruments, Inc. United States
Mettler Electronics Corp. United States
Mi-Med Supply Co., Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 22, 2015
--
Merger/Acquisition
September 4, 2014
Allegro Diagnostics Corp.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Veracyte, Inc., please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.